Developer of small molecule therapies to treat cancer. The therapies target genetic mechanisms to create neoantigen which stimulates the immune system. The company engages in the inactivation of the DNA mismatch repair (MMR) gene which promotes neoantigen creation and provides immunity against numerous cancers. The company was founded in 2017 and headquartered in Cambridge, United Kingdom. It has raised $44.6M in series b funding, with backing from Claris Ventures, Astellas Venture Management, 3B Future Health Fund, 2Invest, and others. The company operates in the Life Sciences - Genomics, Life Sciences - Oncology space. Its offerings span Oncology - Drugs - Pan Cancer and Genomics - Genomics Research - Biomarker Discovery.
← All startups
NeoPhore
Series BDeveloper of small molecule therapies to treat cancer. The therapies target genetic mechanisms to create neoantigen which stimulates the immune system. The company engages in the inactivation of the DNA mismatch repair (MMR) gene which promotes neoantigen creation and provides immunity against numerous cancers. The company was founded in 2017 and headquartered in Cambridge, United Kingdom. It has raised $44.6M in…
About
Business model
Oncology > Drugs > Pan Cancer,
Genomics > Genomics Research > Biomarker Discovery
Team background
College Wise > Harvard University
Institutional investors
Claris VenturesAstellas Venture Management3B Future Health Fund2InvestCancer Research HorizonsSixth Element CapitalParkwalkBristol-Myers Squibb2invest AGNeva SGRLIFTTo2h ventures
Latest coverage
📰 Browse funding news — rounds, valuations, and market moves for founders.
Backed by funds in our directory
🗂️ See who's investing in Life Sciences — full fund directory with check size and geography.